Question

IN all the eividenc that i have found is alll crispir used in all evidence is CRISPR-Cas9 or is there any other type if crispr

The main point of this evidence is that high frequencies of gene editing with CRISPR-Cas9 were observed in CD34+ HSPCs from healthy donors, leading to an increase in fetal hemoglobin levels in edited cells. This gene editing approach is used to potentially treat or improve disorders related to abnormal hemoglobin production, such as sickle cell disease or beta thalassemia.
Representative sequencing results showed successful HDR correction at the G542X mutation site in mouse lungs after DOTAP40-HDR. CRISPR/Cas9 was used to improve gene correction in lung epithelial cells, offering a potential treatment for cystic fibrosis. The result is promising, as few dividing cell populations can be corrected through HDR. The cloning result confirmed successful gene correction at the G542X mutation site with DOTAP40-HDR treatment.
Figure 4 shows that CRISPR b significantly increased γ-globin expression in K562 cells compared to untreated cells, while CRISPR a and c did not. This indicates that CRISPR b effectively targeted the SOX6 binding site to elevate γ-globin levels, demonstrating the potential of CRISPR/Cas9 for enhancing fetal hemoglobin production as a therapeutic approach for β-thalassemia.s
Panel C shows that CRISPR gene editing significantly increased fetal hemoglobin (HbF) as a percentage of total hemoglobin in erythroid cells from 10 healthy donors, with error bars indicating the standard deviation of the results.
The paragraph discusses the treatment and outcomes of patients with β-thalassemia who underwent hematopoietic stem cell transplantation (HSCT) and received BCL11A enhancer-editing therapy.
"White blood cell (WBC) and lymphocyte counts increased after transplantation (Fig. 1a,b), accompanied by the recovery of the cell counts of other subtypes, and were stabilized in a normal range (Fig. 1c–f and Extended Data Fig. 1 (A))."
This part describes the post-transplantation observation of an increase in WBC and lymphocyte counts. It also notes that the counts of other cell subtypes recovered and stabilized within a normal range. This stabilization in the normal range indicates successful engraftment and functioning of the transplanted cells, contributing to the overall health and immune function of the patients.

Answer 1

[AI-generated answer — Bot GPT 3.5]

It appears that the evidence presented primarily focuses on the use of CRISPR-Cas9 technology for gene editing in various applications, such as increasing fetal hemoglobin levels in cells to potentially treat disorders like sickle cell disease and beta thalassemia, as well as improving gene correction in lung epithelial cells for cystic fibrosis treatment. The evidence also highlights the successful outcomes of patients with β-thalassemia who underwent hematopoietic stem cell transplantation and received BCL11A enhancer-editing therapy. While CRISPR-Cas9 is the main type of CRISPR technology mentioned in this evidence, it is possible that other types of CRISPR systems could be used in similar applications, but further research would be needed to confirm this.